Abigail Brooks, MA

Kumar explains what is known about the use of PPAR agonists in primary biliary cholangitis and the significance of the recent FDA accelerated approvals of elafibranor and seladelpar.

Results suggest the potential utility of several nutritional indexes for reflecting IgAN severity and predicting end-stage renal disease risk.

Findings link greater thiazide doses to increased reductions in urine calcium and fewer subsequent symptomatic kidney stone events.

Strnad explains how although moderate alcohol consumption is likely tolerable in most individuals with AATD, careful monitoring of liver-related parameters is still important.

Care for dialysis patients often focuses on kidney health, but experts and a patient stress the need for interdisciplinary care that also addresses sleep health.

Findings suggest the benefit of early HCV detection and treatment with DAAs for improving liver-related outcomes and reducing fibrotic burden.

Estimates based on NHANES data suggest 15.6 million US adults have used a potentially hepatotoxic botanical herbal and dietary supplement product within the past 30 days.

Results suggest paternal hepatitis B virus infection prior to pregnancy is associated with a 40% increased risk of congenital heart diseases in their children.

Alkhouri describes how Agile 3 + and Agile 4 scoring may help address issues with low positive predictive value seen with other noninvasive tests for MASLD fibrosis and cirrhosis.

Moderate alcohol consumption did not significantly impact liver-related parameters in patients with the Pi*MZ and Pi*ZZ genotypes of alpha-1 antitrypsin deficiency.

Findings from the bidirectional 2-sample Mendelian randomization study suggest a strong positive causal association between atopic dermatitis and IgAN.

Strnad explains the need for noninvasive biomarkers in AATD liver disease and early research about circulating Z-polymer’s potential association with clinically relevant adverse outcomes.

High-risk alcohol use was linked to greater rates of cirrhosis in patients with HCV but did not significantly impact rates of sustained virologic response.

The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).

Noureddin explains the discordance between FIB-4 and transient elastography for stratifying fibrosis risk and emphasizes the importance of repetition and attentiveness with FIB-4.

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes.

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

Alkhouri explains the value of AGILE 3+ and AGILE 4, reviewing key findings from a recent study applying the scores to NHANES data to estimate MASLD fibrosis and cirrhosis.

Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals.

Results suggest discordance between FIB-4 and liver stiffness measurement for MASLD-related fibrosis risk stratification.

Findings from a prespecified secondary analysis of the reduced-dose cohort of the TESTING trial suggest the efficacy of a lower dose of oral methylprednisolone in IgA nephropathy.

Positive topline results from the phase 3 VALIANT study show promise for pegcetacoplan in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

Treatment with GLP-1 RAs led to improvements in weight loss, liver function tests, and liver fat in patients with diabetes and MASLD, with hepatic improvements independent of weight loss.

Study findings suggest the need for individualized management of patients with IgAN following COVID-19 infection based on baseline renal function status.

Use of illicitly manufactured fentanyl was linked to a 64% increased risk of acquiring hepatitis C infection among people who inject drugs.

Nearly one-third of eligible patients declined HIV/HCV testing, with notable sex-based differences observed among non-Hispanic Black patients.

Noureddin reviews key considerations for starting, monitoring, and discontinuing treatment with resmetirom in patients with noncirrhotic MASH.

Strnad explains how findings from the SEQUOIA study inform fazirsiran’s use in patients with AATD-associated liver disease and its further evaluation in future phase 3 trials.

New expert panel recommendations outline considerations for initiating and monitoring resmetirom treatment in patients with MASH and moderate fibrosis.